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Abstract
Despite 21st century definitions, the management of acute kidney
injury remains steadfastly rooted in the 20th century with treatment
being principally supportive. Protection from potential causative
agents is an essential part of management and to that end
protection against contrast-induced nephropathy has received yet
more attention. When optimization of volume status, haemo-
dynamic parameters, electrolyte and acid-base disturbances have
failed we turn to renal replacement therapy. The time ‘bought’ on
renal support gives a period for renal recovery but although renal
replacement therapy is widely employed, many management issues
remain unanswered, including the timing, duration and the dose of
treatment. In contrast to respiratory support for acute lung injury,
for example, there is a paucity of large randomized studies
addressing these fundamental issues. We describe some recent
studies focusing on these issues with the hope that they may lead
to better treatment for our patients.
The epidemiology and outcome of acute kidney injury (AKI)
continues to be a subject of much interest, not least because
of the significant mortality, morbidity and costs associated
with it. To this end the recent study by Thakar and colleagues
[1] provides further insights. This is a large retrospective
observational study conducted on data collected between
2001 and 2006 in over half a million consecutive ICU
admissions. AKI was defined using slightly modified Acute
Kidney Injury Network (AKIN) criteria and categorised into
three stages with a logistic regression model applied using
various independent predictors. In essence, this study adds
to the groundswell of opinion that AKI is more than just a
harmless complication of critical illness [2,3]. Small elevations
in creatinine were associated with an increased risk of
mortality, and interestingly, and perhaps intuitively, renal
recovery translated to outcome benefit. Therefore, facilitating
recovery in AKI may offer a distinct therapeutic target that we
should continue to strive for.
One of the most studied causes of AKI is contrast-induced
nephropathy (CIN). This is due, in part, to the fact that it is
easily quantified, but it does also contribute to the burden of
AKI and given the significance of relatively small rises in
creatinine, it cannot be ignored. Two recent articles have
once again examined potential protective strategies in CIN.
Vasheghani-Farahani and colleagues [4] investigated the
added benefit of using sodium bicarbonate in addition to
0.9% saline when compared to 0.9% saline alone in patients
with chronic kidney disease undergoing coronary angio-
graphy. The study included 265 patients, with CIN defined by
the usual criteria (creatinine rise >0.5 mg/dL at 2 and 5 days
post-contrast). Little difference was observed between the
treatment and control arms (13% versus 8.6%), although the
study was somewhat underpowered. A further paper by
Majumdar and colleagues [5] attempted to test the protective
effect of mannitol and furosemide by creating a forced-
diuresis while maintaining euvolaemia with 0.45% saline in a
similar patient group. The results are far from encouraging.
The incidence of CIN was greater than expected and
significantly worse in the forced diuresis group (50% versus
28%). These studies join the cohort of papers that show little
or no clinically relevant benefit in protecting against CIN. In
order to reduce this complication, we should focus our
energies on those measures we know that do work. Strate-
gies to avoid intravascular depletion or omitting diuretics,
nephrotoxins and renal haemodynamic agents are simple but
often incompletely instituted. Getting these aspects right
could arguably produce more convincing evidence of benefit
for our patients than the persistent quest to find the CIN
‘magic pill’. In the meantime we are left waiting for the
definitive trial on the definitive treatment: whatever that may
prove to be.
Despite our best efforts, critically ill patients do, on occasion,
require renal support in whatever guise whereas the mainstay
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of chronic renal support remains outpatient haemodialysis. In
this setting the dose is commonly quantified in terms of urea
kinetics, with urea acting as a surrogate for the clearance of
other low-molecular-weight solutes, and there is much
evidence that higher dosing regimes are translated into
improved outcomes. As a consequence, nephrologists and
intensivists alike have embraced the idea that ‘high-dose’
replacement therapy in the ICU setting must be a good thing.
Indeed, initial study seemed to support this [6]. Unfortunately,
multi-centre studies do not seem to support this and a recent
study published in the New England Journal of Medicine
does not lend any further evidence in support of this practice
[7]. The Randomized Evaluation of Normal versus Augmented
Level Replacement Therapy Study (RENAL) randomly
assigned 1,508 ICU patients who required renal support, of
which 1,464 were assessed, to receive continuous veno-
venous hemodiafiltration at one of two ‘doses’. Patients were
either allotted to a  total effluent flow rate of 25 ml/kg body
weight per hour or 40 ml/kg body weight per hour with
treatment continued until recovery of kidney function or
discharge from intensive care. The primary outcome being
death from any cause at 90 days, secondary outcomes were
the usual suspects of need for mechanical ventilation, death
within 28 days, death in ICU and cessation of renal replace-
ment therapy (RRT). There was no difference in primary
outcome, with 44.7% of patients dying in the first 90 days
after randomization. Encouragingly, 94.4% of patients who did
survive to 90 days no longer required dialysis with similar
rates of renal recovery in both treatment groups. Unsur-
prisingly, the higher dose group demonstrated lower values
for the conventional markers of renal function, an increase in
the number of filters employed and, more worryingly, an
increase in hypophosphataemia. Perhaps one of the most
remarkable statistics was the similarity in fluid balance
between the two groups, with mean daily balances of just
20 ml being achieved. This is a unique study in that all
patients received only continuous therapies and the study
therapy was discontinued in dialysis-dependent patients
when they left ICU, in contrast to the Acute Renal Failure Trial
Network Study [8]. However, no improvement in outcomes
with more intensive RRT was demonstrated. So, does this
mean that the dose delivered does not matter? We would
argue that it does, it is just that the threshold of that dose is
yet to be ascertained and perhaps we have been a little
enthusiastic regarding the dose prescription; therefore, one
wonders whether ‘low dose is the new high dose’ (JA Kellum,
personal communication). What is clear is that in common
with most studies the dose prescribed is rarely achieved and
surely this must be the aim in order to optimize clinical
outcomes, although 88% of patients did achieve the lower
dose regime. Increasing the intensity of therapy beyond the
‘new high dose’ may not confer additional clinical benefit.
Finally, a study on cessation of therapy. A further subgroup
analysis of the BEST kidney data (Beginning and Ending
Supportive Therapy for the Kidney) has examined the clinical
parameters associated with successful cessation of
continuous RRT [9]. This post hoc analysis examined 529
patients. Of these, 313 patients were removed successfully
from RRT and did not require any RRT for at least 7 days;
these were classified as the ‘success’ group. The remaining
216 patients were classified as the ‘repeat-RRT’ group.
Those in the ‘success’ group had a lower hospital mortality
(28.5% versus 42.7%, P < 0.0001) but also had a lower
burden of chronic kidney disease and, perhaps unsur-
prisingly, lower creatinine and urea concentrations as well as
increased urine output. Patients on haemodialysis also
seemed to fare less well. Conventional markers also demon-
strated improvements with lower creatinine and urea
concentrations observed as well as a higher urine output at
the time of RRT cessation. Multivariate logistic regression
identified urine output in the 24 hours prior to stopping RRT
and absolute creatinine concentration as significant predic-
tors for successful cessation. Interestingly, the predictive
ability of urine output was negatively affected by the use of
diuretics. Perhaps the most practical aspect of this study is
that patients who produce more than 400 ml/day of urine
without diuretics or >2,300 ml/day with diuretics have a
greater than 80% chance of successful discontinuation of
continuous RRT. Although further prospective studies are
needed to test this observation, it may be the first evidence
available that can guide our treatment.
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